Mixed Hyperlipidemia denials in California external review
In the California DMHC record, independent physician reviewers decided 12 published external-review cases involving mixed hyperlipidemiaand overturned the plan’s denial in 25%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 6 | 33.3% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 6 | 16.7% |
What the reviewers wrote
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for the computed tomography (CT) scan of the heart without dye with calcium test for evaluation of the enrollee’s chest pain, abnormal electrocardiogram, and mixed hyperlipidemia. Findings: Two physician reviewer found that Use of the calcium score has been supported by the American College of Cardiology (ACC) as a class IIa or IIb category, which states that this testing may be beneficial in asymptomatic individuals with intermediate coronary risk. Other studies such as exercise testing or coronary angiography are recommended in symptomatic individuals. Since this individual was having chest pain and abnormal EKG with right bundle branch block pattern and past history of syncope, the contrast CT coronary angiogram was indicated, but calcium scoring is not recommended in symptomatic patients.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Zepbound. The U.S. Food and Drug Administration (FDA) approved Zepbound for weight management in patients with obesity and at least one comorbidity related to being obese. In addition to obesity, this patient has a history of obesity-related comorbidities, including obstructive sleep apnea (OSA) and mixed hyperlipidemia. The medical literature supports the use of Zepbound for the treatment of obesity, OSA, and mixed hyperlipidemia in conjunction with dietary and lifestyle changes. Moreover, on 12/20/24, the FDA approved Zepbound for the treatment of moderate to severe OSA in adults with obesity. In this case, the patient has a history of obesity and OSA.
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for advanced lipoprotein testing. Findings: The physician reviewer found that the records provided for review document that this patient has a family history of coronary artery disease and diagnoses of mixed hyperlipidemia, low high-density lipoprotein (HDL) cholesterol, mild obstructive sleep apnea (OSA), low serum vitamin D, elevated liver enzymes, and essential hypertension. The patient underwent evaluation with advanced lipoprotein testing. In this circumstance, guidelines for the management of cardiac risk established by the American College of Cardiology (ACC) and American Heart Association (AHA) do not support routine advanced lipoprotein testing (Stone, et al.).
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for cardiac computed tomography (CT) with calcium scoring. Based on the records provided for review, this patient presents with significantly increased coronary risk including mixed hyperlipidemia, abnormal serum protein electrophoresis test results, atypical chest pain, and prediabetes. In this circumstance, the clinical guidelines do not recommend routine performance of specialized tests in the context of assessing coronary risk including coronary calcium quantification, cardiac CT scanning, advanced lipoprotein analysis, genetic testing, and homocysteine.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving mixed hyperlipidemia, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY